Alpha Tau Medical heads into its June 2 results with a wave of fresh analyst conviction that sharply contrasts with the stock's turbulent recent price action.
The analyst story is the standout here. Barclays initiated coverage with an Overweight rating and a $15 target just last week — a meaningful endorsement from a bellwether firm for a clinical-stage oncology name. That follows a cluster of upgrades and target raises through May: HC Wainwright lifted its target to $15, and Ladenburg Thalmann raised to $14. Piper Sandler remains the lone hold-out at Neutral, though even it raised its target from $5 to $8, a 60% lift. The consensus buy rating and mean target of $13.80 imply roughly 43% upside from current levels. The bull case centers on the Alpha DaRT platform's positive interim data in recurrent glioblastoma and an expanding pipeline across solid tumors. Bears point to the long road ahead — no commercial revenue, accelerating cash burn, and limited efficacy data outside of pancreatic and brain indications.
That optimism sits in uneasy tension with the stock's immediate price action. DRTS fell nearly 11% on Monday to $9.67, erasing part of a 13% gain built over the prior month. Despite that one-day drop, the stock is still up sharply year-to-date, driven by clinical catalysts. The options market reflects a mildly more cautious tilt into the print — the put/call ratio has edged up to 0.15, slightly above its 20-day average of 0.14, though the z-score of 1.4 suggests positioning is elevated but not extreme. Overall, options traders are not aggressively hedging; the volume profile skews decisively toward calls, which is consistent with the bullish analyst narrative.
Short interest is low but moving. At 1.6% of the free float, bearish positioning is not a meaningful pressure point — but that figure has risen 84% over the past month and 22% over the past week, a rate of accumulation worth watching. Borrow conditions have actually loosened considerably. Availability has jumped to 194%, up from as low as 7% in late April, meaning shares to borrow are plentiful relative to current short interest. Cost to borrow has eased to 8.2%, down from a mid-May peak near 15%. This is not a short-squeeze setup; it is a stock where incremental bearish positioning is building gradually, without any near-term squeeze catalyst.
Institutional ownership adds texture to the picture. Oramed Pharmaceuticals holds a 16% stake, and ARK Investment Management initiated a new position in April — two very different investor types anchoring the register. Past earnings prints have been consistently positive: the last four events all produced one-day gains between 3% and 7%, with two of those prints sustaining five-day follow-through gains above 13%. Today's report will test whether Alpha DaRT's clinical momentum can justify the premium that analysts are asking investors to hold through ahead of what remains a long commercialization runway.
See the live data behind this article on ORTEX.
Open DRTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
